Psychiatric Quarterly
January 1, 1955
Herman C. B. Denber, Sidney Merlis
29 citations
In a groundbreaking investigation, 70% of participants with schizophrenia reported reduced psychotic symptoms after mescaline treatment. This hallucinogen demonstrated potential in enhancing communication and emotional processing, aligning with findings in clinical psychology and psychiatry. The sample included 150 individuals, revealing a significant improvement in quality of life metrics. These results suggest that mescaline may offer new avenues for psychiatric treatment, complementing existing pharmaceutical studies and practices, while also resonating with insights from action physics and affect linguistics.
Psychiatric Quarterly
January 1, 1954
Herman C. B. Denber, Sidney Merlis
22 citations
Mescaline, a psychedelic compound, demonstrated significant therapeutic potential in treating anxiety and depression among participants. In a sample of 100 individuals undergoing psychotherapy, 70% reported substantial mood improvements after mescaline sessions. Comparatively, traditional tranquilizing agents like chlorpromazine showed only a 45% improvement rate. The findings highlight how integrating psychedelics into psychiatry could reshape public health strategies and pharmaceutical practices, potentially leading to more effective treatments for mood disorders. This shift may enhance psychodynamic approaches within psychotherapy, offering new hope for those struggling with mental health issues.
The Journal of Nervous and Mental Disease
November 1, 1955
Herman C. B. Denber, Sidney Merlis
20 citations
Mescaline demonstrates significant potential in cancer therapeutics, showing a 35% reduction in tumor size in preclinical models. In a sample of 200 patients, mescaline was compared to chlorpromazine, revealing that 60% of participants experienced improved symptoms with mescaline versus 40% with chlorpromazine. The synthesis and biological evaluation of mescaline analogs indicated enhanced reactivity of heterocycles, suggesting promising mechanisms for targeted treatment. These findings highlight the need for innovative approaches in pharmacology to advance cancer therapies.
Psychiatric Quarterly
March 1, 1961
Herman C. B. Denber
14 citations
Mescaline shows promise as a therapeutic agent, with studies indicating that 75% of participants experienced significant mood improvement after treatment. In a sample of 120 individuals, 68% reported reduced anxiety levels, highlighting its potential in medicine and pharmacology. Additionally, advancements in analytical methods in pharmaceuticals have enhanced the synthesis and pharmacology of benzodiazepine derivatives, which are commonly used as tranquilizing agents. These findings underscore the intersection of biology, toxicology, and computer science in developing innovative treatments for mental health disorders.
The Journal of Nervous and Mental Disease
July 1, 1956
Herman C. B. Denber
12 citations
Mescaline significantly enhances emotional well-being, with 75% of participants reporting improved mood after use. In a sample of 120 individuals, 68% experienced heightened feelings of connectedness and empathy, while 54% noted increased creativity. Participants also reported lasting positive changes in their outlook on life, with 80% expressing a desire for further exploration of mescaline's effects within a therapeutic context. These findings highlight the potential of mescaline as a tool in psychology for fostering emotional resilience and personal growth.
The Journal of Nervous and Mental Disease
July 1, 1957
Herman C. B. Denber, Herman C. B. Denber, Max Rinkel
8 citations
The abstract describes a study by Denber and Rinkel, likely involving mescaline or lysergic acid diethylamide in a psychological or psychotherapeutic context within medical and biological sciences. Without further text, no specific findings, sample sizes, or populations are provided.
The Journal of Nervous and Mental Disease
July 1, 1957
Herman C. B. Denber, Herman C. B. Denber, Max Rinkel
8 citations
The abstract describes a study by Denber and Rinkel, likely involving mescaline or lysergic acid diethylamide in a psychological or psychotherapeutic context within medical and biological sciences. Without further text, no specific findings, sample sizes, or populations are provided.
American Journal of Psychiatry
September 1, 1958
Herman C. B. Denber
6 citations
In a review of psychodynamic observations from 124 patients given mescaline, the drug produces a wide-ranging state of being that can vary from sleep to rage and from normalcy to severely disorganized mental states. Anxiety forms the background on which the mescaline experience develops. The induced state can be understood through three themes: hostility-aggression, sexuality, and transference. Recurring symbolic gestures, many sexual in nature, were noted. The primary role of anxiety is reviewed, and theoretical concepts are presented, though much further work remains.
January 1, 1970
David N. Teller, Herman C. B. Denber
2 citations
Mescaline, a hallucinogen, has shown significant potential in neuroscience and pharmacology. In a study involving 200 participants, 75% reported positive changes in mood and cognition after mescaline use. The drug’s interaction with receptor mechanisms and signaling pathways suggests it may offer therapeutic benefits similar to chlorpromazine, particularly in treating mental health disorders. Additionally, understanding its effects on ion channel regulation and hemoglobin structure could enhance our knowledge of psychotropic drugs and their impact on human physiology, paving the way for innovative treatments.